An MD An­der­son study points to an­oth­er use for No­var­tis’ GSK-born can­cer drugs

Though ap­proved, the pre­ci­sion on­col­o­gy drugs No­var­tis grabbed in the famed can­cer-for-in­fec­tious dis­ease swap with Glax­o­SmithK­line are still in stud­ies for new pop­u­la­tions and they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER